These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 31364164

  • 1. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.
    Gui F, Jiang J, He Z, Li L, Li Y, Deng Z, Lu Y, Wu X, Chen G, Su J, Song S, Zhang YM, Yun CH, Huang X, Weisberg E, Zhang J, Deng X.
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [Abstract] [Full Text] [Related]

  • 2. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, Woyach JA, Johnson AJ, Byrd JC, Crews CM.
    Biochemistry; 2018 Jul 03; 57(26):3564-3575. PubMed ID: 29851337
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
    Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL.
    Leukemia; 2015 Apr 03; 29(4):895-900. PubMed ID: 25189416
    [Abstract] [Full Text] [Related]

  • 7. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X, Yang D, Fan Z, Zhang N, Zhao B, Huang C, Wang F, Ma R, Meng M, Deng Y.
    Eur J Med Chem; 2019 Sep 15; 178():767-781. PubMed ID: 31234030
    [Abstract] [Full Text] [Related]

  • 8. PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia.
    Kong C, Wu M, Lu Q, Ke B, Xie J, Li A.
    Leuk Res; 2024 Sep 15; 144():107548. PubMed ID: 39018782
    [Abstract] [Full Text] [Related]

  • 9. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM, Mato AR.
    Drug Des Devel Ther; 2021 Sep 15; 15():919-926. PubMed ID: 33688166
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J.
    Oncotarget; 2015 Jun 20; 6(17):15122-36. PubMed ID: 25944695
    [Abstract] [Full Text] [Related]

  • 12. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ, Song PR, Dou D, Diao YY, Tong LJ, Zhang T, Xie H, Li HL, Ding J.
    Acta Pharmacol Sin; 2020 Mar 20; 41(3):415-422. PubMed ID: 31316181
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
    Bödör C, Kotmayer L, László T, Takács F, Barna G, Kiss R, Sebestyén E, Nagy T, Hegyi LL, Mikala G, Fekete S, Farkas P, Balogh A, Masszi T, Demeter J, Weisinger J, Alizadeh H, Kajtár B, Kohl Z, Szász R, Gergely L, Gurbity Pálfi T, Sulák A, Kollár B, Egyed M, Plander M, Rejtő L, Szerafin L, Ilonczai P, Tamáska P, Pettendi P, Lévai D, Schneider T, Sebestyén A, Csermely P, Matolcsy A, Mátrai Z, Alpár D.
    Br J Haematol; 2021 Jul 20; 194(2):355-364. PubMed ID: 34019713
    [Abstract] [Full Text] [Related]

  • 15. Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase.
    Zhang D, Xu G, Zhao J, Wang Y, Wu X, He X, Li W, Zhang S, Yang S, Ma C, Jiang Y, Ding Q.
    Eur J Med Chem; 2021 Dec 05; 225():113724. PubMed ID: 34391034
    [Abstract] [Full Text] [Related]

  • 16. New Means and Challenges in the Targeting of BTK.
    Nawaratne V, Sondhi AK, Abdel-Wahab O, Taylor J.
    Clin Cancer Res; 2024 Jun 03; 30(11):2333-2341. PubMed ID: 38578606
    [Abstract] [Full Text] [Related]

  • 17. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
    Huang W, Wang S, Zhang Z, Zhang C, Zeng S, Liang M, Shen Z, Liu X.
    Bioorg Chem; 2020 Dec 03; 105():104377. PubMed ID: 33091668
    [Abstract] [Full Text] [Related]

  • 18. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
    Das D, Wang J, Hong J.
    Curr Top Med Chem; 2022 Dec 03; 22(20):1674-1691. PubMed ID: 35927919
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
    Woyach JA.
    Clin Adv Hematol Oncol; 2021 Jul 03; 19(7):436-438. PubMed ID: 34236341
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.